このエントリーをはてなブックマークに追加
ID 49111
フルテキストURL
著者
Sugiura, Yuko Okayama Univ
Soga, Yoshihiko Okayama Univ ORCID Kaken ID publons researchmap
Yamabe, Kokoro Okayama Univ
Tsutani, Soichiro Okayama Univ
Tanimoto, Ichiro Okayama Univ Kaken ID publons
Maeda, Hiroshi Okayama Univ Kaken ID publons
Kokeguchi, Susumu Okayama Univ
Fujii, Nobuharu Okayama Univ Kaken ID publons researchmap
Ishimaru, Fumihiko Okayama Univ
Tanimoto, Mitsune Okayama Univ Kaken ID publons researchmap
Nishimura, Fusanori Okayama Univ
Takashiba, Shogo Okayama Univ ORCID Kaken ID publons researchmap
抄録
The commercial saliva substitute OralbalanceA (R) has been reported to alleviate symptoms of postradiotherapy xerostomia in head and neck cancer patients. OralbalanceA (R) may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are in a severely compromised condition, and saliva substitute must not promote infection. We reported previously that OralbalanceA (R) has antimicrobial effects against microbial species detected during HCT in vitro. This study was performed to determine the in vivo effects of OralbalanceA (R) on oral mucosal total bacterial counts in patients undergoing HCT. A total of 18 neutropenic patients undergoing HCT were enrolled in this study. Before and after 1 week of OralbalanceA (R) use, bacterial samples were obtained from patients by wiping an area of I center dot 1 cm on the buccal mucosa with sterilized cotton swabs. Total bacterial counts of the obtained samples were examined by quantitative polymerase chain reaction amplification of the bacterial 16S ribosomal RNA gene. As controls, bacterial samples were also obtained from ten healthy subjects, and total bacterial counts were examined. No significant increase in bacterial count was observed with use of OralbalanceA (R). None of the patients showed bacterial counts above the range found in healthy controls after using OralbalanceA (R). In neutropenic patients undergoing HCT, OralbalanceA (R) did not increase the total counts of oral mucosal bacteria beyond the range found in healthy controls. Oral care using OralbalanceA (R) may alleviate the symptoms induced by hyposalivation without promoting infection.
キーワード
Hematopoietic cell transplantation
Xerostomia
Saliva substitute
発行日
2010-03
出版物タイトル
Supportive Care in Cancer
18巻
3号
開始ページ
395
終了ページ
398
ISSN
0941-4355
資料タイプ
学術雑誌論文
オフィシャル URL
http://dx.doi.org/ 10.1007/s00520-009-0789-x
言語
英語
論文のバージョン
author
査読
有り
DOI
PubMed ID
Web of Science KeyUT